Cancer Cell Therapy Landscape

The CRI Anna-Maria Kellen Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis of cancer cell therapy based on information collected from numerous trusted and publicly available sources. We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication. 

Interactive dashboard: The top graph serves as the filter to curate the following two graphs. Seven different classes of cell therapies are defined based on their mechanism of actions. More details and other analyses can be found in the Nature Reviews Drug Discovery article published in June 2022.

Cancer Cell Therapies: Publications

The most recent cancer cell therapy landscape publication is “Landscape of cancer cell therapies: trends and real-world data” in Nature Reviews Drug Discovery (June 2022).

Please note that all landscape dashboards are integrated with the CRI iAtlas for further exploration of the molecular targets. 

Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.

Subscribe to our email newsletter to receive the latest updates on our landscape analyses.

Do you want more information on the Clinical Accelerator? Contact us. 

IO Landscapes

Immuno-Oncology Landscape

Cancer Cell Therapy Landscape

PD-1/PD-L1 Immune Checkpoint Inhibitors Landscape

Pancreatic Cancer IO Landscape

Regulatory Approval Timeline of Active Immunotherapies

COVID-19 and Clinical Trials